The stone drug Ouedasatini tablets are about to be approved for sale

Recently, the stone drug Oyi according to 4 categories of submitted Dasatini tablets listed application in the "in the approval" state, is expected to be approved in the near future, becoming the first variety through the consistent evaluation of manufacturers.
dasatinib is a tyrosine kinase inhibitor that inhibits BCR-ABL kinases and SRC family kinases, as well as many other selective carcinogenic kinases, including c-KIT, ephrin (EPH) subject kinases, and PDGF beta.
Dasatini is currently approved in the country for the treatment of adult patients with methyl sulfonate imatinoid resistance, or insatiable Philadelphia chromosomal-positive (Ph-plus) chronic myeloid leukemia (CML) chronic, accelerated and rapidly changing periods (rapid granulation and rapid gonorrhea).
Dasatini, developed by BMS, was first approved by the FDA in 2006 to treat patients with imatinoid-resistant, or insatiable Philadelphia chromosomal-positive (Ph-plus) chronic myeloid leukemia (CML) chronic, accelerated adult patients.
was followed by four new adaptations: (1) the treatment of newly diagnosed adult patients with chronic stage Ph-CML; (2) the treatment of adult patients with previously drug-resistant or insatiable Ph-acute lymphoblastic leukemia (Ph-ALL); (3) children aged 1 and over with the chronic period of Ph-CML; and (4) the combination of chemotherapy to treat newly diagnosed Ph-ALL-paediatric patients aged 1 and over.
2.11 billion U.S. dollars in 2019.
Source: Pharmaceutical Rubik's Cube NextPharma In August 2011, the State Drug Administration approved the domestic market of dasateni original research drugs, in September 2013 Zhengtian Qing da Shatini's first generic drug was approved for market, and in December 2019 submitted a consistent evaluation application, is now in the "approval" stage.
currently only BMS original research and Zhengda Tianqing's first imitation listing in China.
by the CDE clinical trial registration platform can be known, in addition to Zhengda Tianqing, stone medicine European-Italian registration BE research, Nanjing Yuke has completed the BE research, Shandong New Era this year registration, is currently in the process.
other listed Bcr-Abl inhibitors are Imatinini, Radotinib, ponatinib, bosutinib, nilotinib, fluoromartinib, and only Imatini, Nilotini, Dasatini, fluoromatinib, 4 Bcr-Abl inhibitors.
is the first BCR-ABL tyrosine kinase inhibitor to be marketed and the world's first small molecule-targeted cancer drug.
Imatinib's listing greatly prolonged the survival of CML patients and quickly became a front-line drug for CML, but with its widespread use, drug resistance was rapidly developed, so second-generation BCR-ABL inhibitors such as dasateni came into being.
combination with BCR-ABL is not as strict as Imatinib's composition requirements and can therefore be used for resistance to all Bcr-Abl kinase mutations except T3151 mutations.
Dasatini VS Imatini binding point Chronic myeloid leukemia (CML) is a malignant tumor formed by the cloning proliferation of myeloid hematopoietic stem cells, accounting for 15% of adult leukemia, with a global annual incidence rate of 1.6 per 100,000 to 2/100,000.
the national leukemia incidence survey conducted in 46 investigation points in 22 provinces (municipalities and autonomous regions) from 1986 to 1988 showed that the annual incidence rate of CML was 0.36 per 100,000.
epidemiological surveys in several parts of the country since then showed an annual incidence rate of 0.39 per 100,000 to 0.55 per 100,000.
chinese CML patients are younger than those in the West, epidemiological surveys in several regions of China show that the median age of CDL is 45 to 50 years, while the median age of CDL in Western countries is 67.
。